RE:RE:RE:Management Information Circular ...EbbFlow88 wrote: It's an advantage for all of us but I don't think they are trying to keep it down.
Agreed - nature of the beast with ~70% of the shares in 270 hands.
The base of owners hasn't really changed.
-----------------------
Here's the kind of scenario I'd be expecting over the next 5 years ...
- purchase a few small drug portfolios for ROW or just a bunch of individual ROW drugs.
- Novartis to pay close attention to GUD/EXELON as they rate GUD's abilities with ROW (remember there is a very large agreement between the two but it is mostly redacted).
- Novartis (or other) to strike a deal ... trade a larger portfolio of ROW drugs for a percent of Knight.
Just my opinion.